On September 26, 2019 Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune disease, asthma and allergic diseases, reported that company management will present at the 2019 Cantor Global Healthcare Conference on Thursday, October 3, 2019 at 8:55 a.m. ET in New York (Press release, Xencor, SEP 26, 2019, View Source [SID1234539821]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast will be available under "Events & Presentations" in the Investors section of the Company’s website located at www.xencor.com. A replay of the event will be posted on the Xencor website approximately one hour after the live event and will be available for 30 days following the presentation.

On September 26, 2019 Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF) and other diseases caused by dysfunctional protein processing, reported that Proteostasis management will present at the 2019 Cantor Global Healthcare Conference on Thursday, October 3, 2019 at 8:55 a.m. ET at the InterContinental New York Barclay (Press release, Proteostasis Therapeutics, SEP 26, 2019, View Source [SID1234539839]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live audio webcast of the Cantor conference presentation will be available on the Investor Events page in the Investors & Media section of the Company’s website, www.proteostasis.com. A replay of the webcast will be available on the Company’s website following the presentation.

On September 26, 2019 BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, reported that clinical data on its investigational anti-PD-1 antibody tislelizumab and its investigational PARP inhibitor pamiparib will be presented in five poster presentations at the European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) Congress 2019, taking place September 27 – October 1, 2019 in Barcelona, Spain (Press release, BeiGene, SEP 26, 2019, View Source [SID1234539857]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Poster Presentations:

Title: Population Pharmacokinetics of Tislelizumab in Patients with Advanced Tumors
Presentation #: 483P
Date: Saturday, September 28
Time: 12:00 – 13:00 CEST
Location: Poster Area (Hall 4)
Presenter: Chi-Yuan Wu, Ph.D., BeiGene

Title: Tislelizumab Exposure-Response Analyses of Efficacy and Safety in Patients with Advanced Tumors
Presentation #: 482P
Date: Saturday, September 28
Time: 12:00 – 13:00 CEST
Location: Poster Area (Hall 4)
Presenter: Chi-Yuan Wu, Ph.D., BeiGene

Title: Updated Results of the PARP1/2 Inhibitor Pamiparib in Combination with Low-dose Temozolomide in Patients with Locally Advanced or Metastatic Solid Tumors
Presentation #: 451PD
Date: Saturday, September 28
Time: 16:30 – 18:00 CEST
Location: Alicante Auditorium (Hall 3)
Presenter: Agostina Stradella, M.D., Catalan Institute of Oncology, Spain

Title: Safety, Antitumor Activity, and Pharmacokinetics of Pamiparib, a PARP1/2 Inhibitor, in Patients with Advanced Solid Tumors: Updated Phase 1 Dose-Escalation/Expansion Results
Presentation #: 452PD
Date: Saturday, September 28
Time: 16:30 – 18:00 CEST
Location: Alicante Auditorium (Hall 3)
Presenter: Mark Voskoboynik, MBBS, FRACP, Nucleus Network, Australia

Title: First Report of Efficacy and Safety from a Phase 2 Trial of Tislelizumab, an Anti-PD-1 Antibody, for the Treatment of PD-L1+ Locally Advanced or Metastatic Urothelial Carcinoma in Asian Patients
Presentation #: 920P
Date: Monday, September 30
Time: 12:00 – 13:00 CEST
Location: Poster Area (Hall 4)
Presenter: Dingwei Ye, M.D., Ph.D., Fudan University Cancer Institute, China

On September 26, 2019 Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, reported that Brandi L. Roberts, Chief Financial Officer, will be presenting at the 2019 Cantor Global Healthcare Conference on October 4th, 2019 at 1:45pm Eastern Time at the InterContinental Barclay Hotel in Grand Ballroom 1 in New York, NY (Press release, Lineage Cell Therapeutics, SEP 26, 2019, View Source [SID1234539806]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On September 26, 2019 Verastem, Inc. (Nasdaq: VSTM) (Verastem Oncology or the Company), focused on developing and commercializing medicines seeking to improve the survival and quality of life of cancer patients, reported that the Company will present at the Cantor 2019 Global Healthcare Conference on Thursday, October 3, 2019 at 8:20 a.m. EDT in New York, NY (Press release, Verastem, SEP 26, 2019, View Source [SID1234539822]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the presentation will be available on the investors section of the Company’s website at www.verastem.com. An archived presentation will be available for 90 days.